Global Cycloplegic Agents Market Growth 2025-2031

Publication ID:

LPI04255195

Publication Date:

April 23, 2025

Pages:

123

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Cycloplegic Agents market size is predicted to grow from US$ 1498 million in 2025 to US$ 2165 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.
Cycloplegic agents act by paralysing the iris"s sphincter muscle, causing dilation, and by paralysing the ciliary muscle, which inhibits accommodation. Atropine, homatropine, scopolamine, cyclopentolate, and tropicamide are examples of cycloplegic agents. Preventing movement of the iris or ciliary body"s dilator and sphincter muscles with cycloplegic drugs often relieves pain in inflammatory conditions such as uveitis and is a standard therapeutic procedure. Furthermore, as a result of the local release of prostaglandins, the iris usually constricts during irritation or inflammation. This makes it easier for adhesions to form with the lens. Cycloplegics also aid in the prevention of this complication.
Cycloplegic drugs are muscarinic receptor blockers. Atropine, cyclopentolate, homatropine, scopolamine and tropicamide are among them. They are approved for use in cycloplegic refraction (paralysing the ciliary muscle to determine the true refractive error of the eye) and uveitis treatment. These are the factors which is expected to grow of the market.
The 鈥淐ycloplegic Agents Industry Forecast鈥� looks at past sales and reviews total world Cycloplegic Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Cycloplegic Agents sales for 2025 through 2031. With Cycloplegic Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cycloplegic Agents industry.
This Insight Report provides a comprehensive analysis of the global Cycloplegic Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cycloplegic Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Cycloplegic Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cycloplegic Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cycloplegic Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Cycloplegic Agents market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Atropine
Cyclopentolate
Houmatopin
Tropicamide
Scopolamine
Segmentation by Application:
Pseudomyopia
Optometry
Uveitis
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer Inc
Henry Schein, Inc
Actiza Pharmaceutical Private Limited
Hameln Pharma Gmbh
Sigma Pharmaceuticals, LLC
Biomedica
Prudence Pharma Chem
Heer Pharma Pvt. Ltd
Fresenius Kabi AG
Bausch Health Companies, Inc
Novartis
Alcon Inc
Akorn, Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cycloplegic Agents market?
What factors are driving Cycloplegic Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cycloplegic Agents market opportunities vary by end market size?
How does Cycloplegic Agents break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cycloplegic Agents Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Cycloplegic Agents by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Cycloplegic Agents by Country/Region, 2020, 2024 & 2031
2.2 Cycloplegic Agents Segment by Type
2.2.1 Atropine
2.2.2 Cyclopentolate
2.2.3 Houmatopin
2.2.4 Tropicamide
2.2.5 Scopolamine
2.3 Cycloplegic Agents Sales by Type
2.3.1 Global Cycloplegic Agents Sales Market Share by Type (2020-2025)
2.3.2 Global Cycloplegic Agents Revenue and Market Share by Type (2020-2025)
2.3.3 Global Cycloplegic Agents Sale Price by Type (2020-2025)
2.4 Cycloplegic Agents Segment by Application
2.4.1 Pseudomyopia
2.4.2 Optometry
2.4.3 Uveitis
2.4.4 Other
2.5 Cycloplegic Agents Sales by Application
2.5.1 Global Cycloplegic Agents Sale Market Share by Application (2020-2025)
2.5.2 Global Cycloplegic Agents Revenue and Market Share by Application (2020-2025)
2.5.3 Global Cycloplegic Agents Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Cycloplegic Agents Breakdown Data by Company
3.1.1 Global Cycloplegic Agents Annual Sales by Company (2020-2025)
3.1.2 Global Cycloplegic Agents Sales Market Share by Company (2020-2025)
3.2 Global Cycloplegic Agents Annual Revenue by Company (2020-2025)
3.2.1 Global Cycloplegic Agents Revenue by Company (2020-2025)
3.2.2 Global Cycloplegic Agents Revenue Market Share by Company (2020-2025)
3.3 Global Cycloplegic Agents Sale Price by Company
3.4 Key Manufacturers Cycloplegic Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cycloplegic Agents Product Location Distribution
3.4.2 Players Cycloplegic Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Cycloplegic Agents by Geographic Region
4.1 World Historic Cycloplegic Agents Market Size by Geographic Region (2020-2025)
4.1.1 Global Cycloplegic Agents Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Cycloplegic Agents Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Cycloplegic Agents Market Size by Country/Region (2020-2025)
4.2.1 Global Cycloplegic Agents Annual Sales by Country/Region (2020-2025)
4.2.2 Global Cycloplegic Agents Annual Revenue by Country/Region (2020-2025)
4.3 Americas Cycloplegic Agents Sales Growth
4.4 APAC Cycloplegic Agents Sales Growth
4.5 Europe Cycloplegic Agents Sales Growth
4.6 Middle East & Africa Cycloplegic Agents Sales Growth
5 Americas
5.1 Americas Cycloplegic Agents Sales by Country
5.1.1 Americas Cycloplegic Agents Sales by Country (2020-2025)
5.1.2 Americas Cycloplegic Agents Revenue by Country (2020-2025)
5.2 Americas Cycloplegic Agents Sales by Type (2020-2025)
5.3 Americas Cycloplegic Agents Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cycloplegic Agents Sales by Region
6.1.1 APAC Cycloplegic Agents Sales by Region (2020-2025)
6.1.2 APAC Cycloplegic Agents Revenue by Region (2020-2025)
6.2 APAC Cycloplegic Agents Sales by Type (2020-2025)
6.3 APAC Cycloplegic Agents Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Cycloplegic Agents by Country
7.1.1 Europe Cycloplegic Agents Sales by Country (2020-2025)
7.1.2 Europe Cycloplegic Agents Revenue by Country (2020-2025)
7.2 Europe Cycloplegic Agents Sales by Type (2020-2025)
7.3 Europe Cycloplegic Agents Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cycloplegic Agents by Country
8.1.1 Middle East & Africa Cycloplegic Agents Sales by Country (2020-2025)
8.1.2 Middle East & Africa Cycloplegic Agents Revenue by Country (2020-2025)
8.2 Middle East & Africa Cycloplegic Agents Sales by Type (2020-2025)
8.3 Middle East & Africa Cycloplegic Agents Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Cycloplegic Agents
10.3 Manufacturing Process Analysis of Cycloplegic Agents
10.4 Industry Chain Structure of Cycloplegic Agents
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Cycloplegic Agents Distributors
11.3 Cycloplegic Agents Customer
12 World Forecast Review for Cycloplegic Agents by Geographic Region
12.1 Global Cycloplegic Agents Market Size Forecast by Region
12.1.1 Global Cycloplegic Agents Forecast by Region (2026-2031)
12.1.2 Global Cycloplegic Agents Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Cycloplegic Agents Forecast by Type (2026-2031)
12.7 Global Cycloplegic Agents Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Pfizer Inc
13.1.1 Pfizer Inc Company Information
13.1.2 Pfizer Inc Cycloplegic Agents Product Portfolios and Specifications
13.1.3 Pfizer Inc Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Inc Main Business Overview
13.1.5 Pfizer Inc Latest Developments
13.2 Henry Schein, Inc
13.2.1 Henry Schein, Inc Company Information
13.2.2 Henry Schein, Inc Cycloplegic Agents Product Portfolios and Specifications
13.2.3 Henry Schein, Inc Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Henry Schein, Inc Main Business Overview
13.2.5 Henry Schein, Inc Latest Developments
13.3 Actiza Pharmaceutical Private Limited
13.3.1 Actiza Pharmaceutical Private Limited Company Information
13.3.2 Actiza Pharmaceutical Private Limited Cycloplegic Agents Product Portfolios and Specifications
13.3.3 Actiza Pharmaceutical Private Limited Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Actiza Pharmaceutical Private Limited Main Business Overview
13.3.5 Actiza Pharmaceutical Private Limited Latest Developments
13.4 Hameln Pharma Gmbh
13.4.1 Hameln Pharma Gmbh Company Information
13.4.2 Hameln Pharma Gmbh Cycloplegic Agents Product Portfolios and Specifications
13.4.3 Hameln Pharma Gmbh Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Hameln Pharma Gmbh Main Business Overview
13.4.5 Hameln Pharma Gmbh Latest Developments
13.5 Sigma Pharmaceuticals, LLC
13.5.1 Sigma Pharmaceuticals, LLC Company Information
13.5.2 Sigma Pharmaceuticals, LLC Cycloplegic Agents Product Portfolios and Specifications
13.5.3 Sigma Pharmaceuticals, LLC Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Sigma Pharmaceuticals, LLC Main Business Overview
13.5.5 Sigma Pharmaceuticals, LLC Latest Developments
13.6 Biomedica
13.6.1 Biomedica Company Information
13.6.2 Biomedica Cycloplegic Agents Product Portfolios and Specifications
13.6.3 Biomedica Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Biomedica Main Business Overview
13.6.5 Biomedica Latest Developments
13.7 Prudence Pharma Chem
13.7.1 Prudence Pharma Chem Company Information
13.7.2 Prudence Pharma Chem Cycloplegic Agents Product Portfolios and Specifications
13.7.3 Prudence Pharma Chem Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Prudence Pharma Chem Main Business Overview
13.7.5 Prudence Pharma Chem Latest Developments
13.8 Heer Pharma Pvt. Ltd
13.8.1 Heer Pharma Pvt. Ltd Company Information
13.8.2 Heer Pharma Pvt. Ltd Cycloplegic Agents Product Portfolios and Specifications
13.8.3 Heer Pharma Pvt. Ltd Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Heer Pharma Pvt. Ltd Main Business Overview
13.8.5 Heer Pharma Pvt. Ltd Latest Developments
13.9 Fresenius Kabi AG
13.9.1 Fresenius Kabi AG Company Information
13.9.2 Fresenius Kabi AG Cycloplegic Agents Product Portfolios and Specifications
13.9.3 Fresenius Kabi AG Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Fresenius Kabi AG Main Business Overview
13.9.5 Fresenius Kabi AG Latest Developments
13.10 Bausch Health Companies, Inc
13.10.1 Bausch Health Companies, Inc Company Information
13.10.2 Bausch Health Companies, Inc Cycloplegic Agents Product Portfolios and Specifications
13.10.3 Bausch Health Companies, Inc Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Bausch Health Companies, Inc Main Business Overview
13.10.5 Bausch Health Companies, Inc Latest Developments
13.11 Novartis
13.11.1 Novartis Company Information
13.11.2 Novartis Cycloplegic Agents Product Portfolios and Specifications
13.11.3 Novartis Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Novartis Main Business Overview
13.11.5 Novartis Latest Developments
13.12 Alcon Inc
13.12.1 Alcon Inc Company Information
13.12.2 Alcon Inc Cycloplegic Agents Product Portfolios and Specifications
13.12.3 Alcon Inc Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Alcon Inc Main Business Overview
13.12.5 Alcon Inc Latest Developments
13.13 Akorn, Inc
13.13.1 Akorn, Inc Company Information
13.13.2 Akorn, Inc Cycloplegic Agents Product Portfolios and Specifications
13.13.3 Akorn, Inc Cycloplegic Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Akorn, Inc Main Business Overview
13.13.5 Akorn, Inc Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂